Amedisys (NASDAQ:AMED) PT Lowered to $165.00

Amedisys (NASDAQ:AMEDGet Rating) had its price objective reduced by Benchmark from $175.00 to $165.00 in a research report sent to investors on Thursday morning, The Fly reports. Benchmark currently has a maintains rating on the health services provider’s stock.

Other equities analysts also recently issued reports about the stock. Bank of America downgraded shares of Amedisys from a neutral rating to an underperform rating and decreased their price target for the stock from $145.00 to $102.00 in a research note on Tuesday, June 21st. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Amedisys from $210.00 to $175.00 and set a buy rating on the stock in a research note on Tuesday, June 21st. Truist Financial decreased their price target on shares of Amedisys from $175.00 to $150.00 and set a buy rating on the stock in a research note on Thursday, July 14th. Stifel Nicolaus started coverage on shares of Amedisys in a research note on Tuesday, June 28th. They issued a hold rating and a $128.00 price target on the stock. Finally, StockNews.com assumed coverage on shares of Amedisys in a research note on Thursday, March 31st. They issued a hold rating on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of Hold and a consensus price target of $160.88.

Amedisys Stock Down 1.8 %

Shares of NASDAQ AMED opened at $119.85 on Thursday. The company’s 50-day simple moving average is $117.81 and its 200-day simple moving average is $135.30. Amedisys has a 52-week low of $101.61 and a 52-week high of $264.10. The firm has a market cap of $3.90 billion, a price-to-earnings ratio of 20.63, a price-to-earnings-growth ratio of 2.48 and a beta of 0.90. The company has a quick ratio of 1.03, a current ratio of 1.03 and a debt-to-equity ratio of 0.42.

Amedisys (NASDAQ:AMEDGet Rating) last announced its earnings results on Wednesday, July 27th. The health services provider reported $1.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.24. Amedisys had a net margin of 8.59% and a return on equity of 19.37%. The business had revenue of $557.89 million for the quarter, compared to analyst estimates of $583.12 million. During the same quarter last year, the business earned $1.69 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts predict that Amedisys will post 5.29 EPS for the current fiscal year.

Insider Buying and Selling at Amedisys

In other Amedisys news, insider Denise M. Bohnert sold 557 shares of Amedisys stock in a transaction dated Thursday, June 23rd. The shares were sold at an average price of $115.00, for a total transaction of $64,055.00. Following the completion of the sale, the insider now directly owns 11,850 shares in the company, valued at $1,362,750. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own 2.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. BlackRock Inc. grew its holdings in shares of Amedisys by 3.7% in the first quarter. BlackRock Inc. now owns 3,896,785 shares of the health services provider’s stock valued at $671,378,000 after purchasing an additional 138,484 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Amedisys by 3.5% in the first quarter. Wellington Management Group LLP now owns 1,875,274 shares of the health services provider’s stock valued at $323,092,000 after purchasing an additional 62,863 shares in the last quarter. Riverbridge Partners LLC grew its holdings in shares of Amedisys by 6.6% in the first quarter. Riverbridge Partners LLC now owns 1,693,656 shares of the health services provider’s stock valued at $291,800,000 after purchasing an additional 104,906 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Amedisys by 23.5% in the first quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock valued at $238,457,000 after purchasing an additional 263,275 shares in the last quarter. Finally, Mackenzie Financial Corp grew its holdings in shares of Amedisys by 67.7% in the first quarter. Mackenzie Financial Corp now owns 956,780 shares of the health services provider’s stock valued at $164,844,000 after purchasing an additional 386,411 shares in the last quarter. Institutional investors and hedge funds own 90.47% of the company’s stock.

Amedisys Company Profile

(Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Articles

The Fly logo

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Want More Great Investing Ideas?

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.